Annovis Bio, Inc.

Zhou v. Annovis Bio, Inc., et al., (Case No. 21-cv-3668), E.D. Pa.

Annovis is a clinical-drug company that develops drugs for the treatment neurodegenerative diseases. After the market close on July 28, 2021, the Company announced that its Alzheimer’s and Parkinson’s drug Posiphen failed to show statistically significant success relative to the placebo. On this news, the stock dropped 60% on July 29, 2021.

Lead Plaintiff deadline
October 18, 2021
class period
May 21, 2021
July 28, 2021
Case Documents
No documents available. Contact us if you need a case document.